Mitochondrial Complex I Deficiency CRISPR Knockout Cell Models

Mitochondrial complex I deficiency is the most common respiratory chain disorder, with an estimated incidence of 1 in 5,000 live births (WHO, 2023). It accounts for approximately 30% of all mitochondrial diseases. Clinical presentation is heterogeneous, ranging from fatal infantile encephalopathy (e.g., Leigh syndrome) to adult-onset myopathy. The 5-year survival for severe infantile forms is less than 20% (NCI, 2022). Key risk factors include maternal inheritance of mtDNA mutations and autosomal recessive nuclear gene mutations.

Complex I deficiency is ideal for mechanistic studies due to its well-defined biochemical phenotype (impaired NADH:ubiquinone oxidoreductase activity) and the availability of public datasets (e.g., MSeqDR, Mitomap). Open questions include tissue-specific vulnerability, the role of reactive oxygen species (ROS), and the potential for gene therapy. Gene-edited cell models enable precise dissection of genotype-phenotype correlations.

The primary defect is in mitochondrial complex I (NADH:ubiquinone oxidoreductase), the first enzyme of the electron transport chain (ETC). Key steps:

1. NADH oxidation: Complex I oxidizes NADH to NAD+, transferring two electrons to FMN.

2. Electron transfer: Electrons pass through a series of iron-sulfur (Fe-S) clusters to ubiquinone (CoQ).

3. Proton pumping: The energy from electron transfer drives translocation of four protons across the inner mitochondrial membrane, contributing to the proton motive force.

4. ATP synthesis: The proton gradient drives ATP synthase (complex V).

In complex I deficiency, impaired electron flow leads to reduced ATP production, increased ROS generation, and accumulation of NADH. This disrupts the NAD+/NADH ratio, affecting multiple metabolic pathways including the TCA cycle and fatty acid oxidation.

Data from TCGA (Pan-Cancer Atlas, 2020) and COSMIC v98 (2023).

Complex I deficiency impacts multiple signaling networks:

• • AMPK signaling: Reduced ATP/AMP ratio activates AMPK, promoting catabolic pathways and inhibiting anabolic processes.
• • mTORC1 signaling: Energy stress suppresses mTORC1, reducing protein synthesis and cell growth.
• • HIF-1α stabilization: Increased ROS and succinate accumulation inhibit prolyl hydroxylases, stabilizing HIF-1α and inducing a pseudohypoxic response.
• • Apoptosis pathways: Mitochondrial dysfunction can trigger cytochrome c release and caspase activation.
• • ROS-mediated signaling: Superoxide production activates JNK and p38 MAPK pathways, contributing to oxidative stress and cell death.

Organoids derived from patient iPSCs recapitulate tissue-specific phenotypes (e.g., brain organoids for Leigh syndrome) and allow 3D modeling of mitochondrial dysfunction.

• • Ndufs4 knockout mouse: Recapitulates Leigh syndrome with progressive encephalopathy and early lethality.
• • Ndufv1 conditional knockout mouse: Tissue-specific deletion in muscle or heart models myopathy and cardiomyopathy.
• • MT-ND5 mutant mouse (mito-mouse): Heteroplasmic mtDNA mutation model for Leber hereditary optic neuropathy (LHON).
• • Zebrafish models: Morpholino or CRISPR-based knockdown of complex I subunits (e.g., ndufs4) for developmental studies.
• • Drosophila models: Knockdown of complex I genes (e.g., ND-75) for neurodegeneration studies.

CRISPR/Cas9 technology enables the generation of isogenic cell lines with precise genetic modifications. Examples include:

• • TP53-/- knockout in HCT116: Eliminates p53-mediated apoptosis, allowing study of complex I deficiency in a controlled background.
• • NDUFS4 knockout in HEK293: Complete loss of complex I activity, validated by seahorse assay.
• • MT-ND1 G3460A knock-in: Models a common LHON mutation using mitochondrial-targeted TALENs or base editors.

Commercially available, sequence-verified gene-edited cell models accelerate research by providing reproducible, isogenic systems for drug screening, functional genomics, and target validation. These models are available from commercial sources and can be customized for specific mutations.

Knockout and knock-in cell lines are used to validate the role of specific genes in complex I assembly and function. For example, NDUFS4 knockout cells show reduced complex I activity and increased ROS, confirming its essential role. Similarly, NDUFV1 missense mutations can be introduced to study substrate binding. These models enable high-throughput CRISPR screens to identify genetic modifiers of complex I deficiency.

Isogenic pairs (wild-type vs. knockout) are used in drug screening to identify compounds that rescue complex I activity or reduce ROS. For example, idebenone and EPI-743 have been tested in NDUFS4 knockout cells. Resistance modeling: cells with complex I deficiency may be resistant to certain chemotherapeutics (e.g., metformin) that rely on mitochondrial function. Gene-edited models allow mechanistic studies of resistance.

CRISPR synthetic lethality screens in complex I-deficient cells identify vulnerabilities that can be targeted therapeutically. For example, NDUFS4 knockout cells are hypersensitive to inhibitors of complex II (e.g., atpenin A5) or glycolysis (e.g., 2-deoxyglucose). These screens reveal potential biomarkers (e.g., elevated lactate/pyruvate ratio) and therapeutic targets (e.g., NAD+ supplementation).